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ABsTrACT
New treatments are required for severe breathlessness 
in advanced disease. We conducted a randomised 
feasibility trial of mirtazapine over 28 days in adults 
with a modified medical research council breathlessness 
scale score ≥3. Sixty- four patients were randomised 
(409 screened), achieving our primary feasibility 
endpoint of recruitment. Most patients had COPD 
or interstitial lung disease; 52 (81%) completed the 
trial. There were no differences between placebo and 
mirtazapine in tolerability or safety, and blinding was 
maintained. Worst breathlessness ratings at day 28 
(primary clinical activity endpoint) were, 7.1 (SD 2.3, 
placebo) and 6.3 (SD 1.8, mirtazapine). A phase III trial 
of mirtazapine is indicated. Trial registration: ISRCTN 
32236160; European Clinical Trials Database (EudraCT 
no: 2015-004064-11).
InTroduCTIon
Breathlessness is a prevalent and distressing 
symptom, associated with considerable disability, 
social isolation, emergency service use and poor 
survival.1 2 It often persists despite optimum phar-
macological treatment of the underlying medical 
condition and non- drug approaches.1 3 4 Drug treat-
ments are limited; opioids have the best evidence,5 6 
but concerns remain regarding long- term effects. 
New treatments are required. Antidepressants 
impact on neurotransmitters involved in various 
brain circuits potentially affecting breathlessness, 
and are worthy of consideration.7 Data are mixed 
for selective serotonin reuptake inhibitors, with 
positive case series but a negative randomised 
controlled trial.8 9 Mirtazapine is an antagonist at 
α2- adrenergic, H1, 5HT2A/C and 5HT3 receptors, 
resulting in serotonin, norepinephrine and dopa-
mine release.7
Thus, we conducted a multicentre, randomised, 
placebo- controlled, double- blind, parallel- group, 
dose- escalating, mixed- methods, feasibility trial 
of mirtazapine for patients severely affected by 
breathlessness, to inform a potential phase III 
trial.
MeThods
For full details, see the Trial Protocol, online supple-
mentary document S1.
Participants
Patients were recruited from three centres. Inclusion 
criteria were: consenting adults with a confirmed 
diagnosis (by hospitals/clinicians) of COPD, inter-
stitial lung disease (ILD), cancer or chronic heart 
failure, plus clinician assessed modified medical 
research council (mMRC) breathlessness score 
of 3 or 4 despite optimal treatment of underlying 
disease(s) and prognosis of ≥2 months. Main exclu-
sion criteria were: existing antidepressant use and 
contraindications to mirtazapine.
Trial design and procedures
Participants were randomised (1:1) to receive 
oral mirtazapine (15 mg/day (evening)) or placebo 
(capsules identical in appearance, smell and taste) 
for 28 days. Randomisation was stratified by 
disease (cancer vs non- cancer), Hospital Anxiety 
and Depression Scale (HADS) score (≥15 vs <15), 
and taking opioids (yes vs no).
The primary endpoint was number of patients 
recruited across three hospitals over 12 months, 
with a target of 60. Secondary endpoints, including 
proposed primary and secondary clinical activity 
outcomes for a main trial, are in online supple-
mentary box S1. Assessments were at baseline 
and weekly thereafter, and included evaluation of 
breathlessness and related activity scales, toxicity, 
treatment adherence and quality of life. At 14 days, 
if the rating of worst breathlessness during the 
previous 24 hours had not improved ≥1 point on 
the 0–10 numerical rating scale (NRS) over base-
line, the daily dose was increased to two capsules 
(placebo or 30 mg mirtazapine).
Semi- structured qualitative interviews with a 
purposive sample of participants, aiming to include 
a mix of diseases, experiences and backgrounds 
(subject to data saturation), explored motivations 
for trial participation and experiences of the inter-
vention, procedures and study measures (see Trial 
Protocol, online supplementary document S1 page 
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Figure 1 Consolidated Standards of Reporting Trials flow diagram of patients included in the trial, follow- up and analysis. #=reasons why seven 
patients were consented but not randomised were because they were found or became ineligible: started pulmonary rehabilitation (1); uncontrolled 
diabetes mellitus (2), started taking antidepressants (1), hepatic impairment (1), decided not on optimal treatment for underlying condition (1), and 
one missing. * Of those who discontinued intervention, patients were willing to continue data collection in all but one in the mirtazapine group and 
all but four in the placebo group, all available data were analysed.
Figure 2 Mean (95% CI) breathlessness at worst and average over 
24 hours during the 28 days of the study, by study arm.
77).
The trial received appropriate approvals from the Medicines 
and Healthcare products Regulatory Agency, London Central 
Research Ethics Committee (16/LO/0091), local research govern-
ance and registrations; International Standard Randomised 
Controlled Trial (32236160); EU Clinical Trials Register (2015-
004064-11); adopted onto the National Institute for Health 
Research portfolio (30471).
Analysis
For the statistical analysis of the primary endpoint (feasibility), 
we predetermined 60 patients had to be recruited over 12 months 
across the centres. This sample size took into account the likely 
number required for a fully powered phase III trial, guidance 
on feasibility designs and number needed to estimate the overall 
SD for the phase III primary outcome of worst breathlessness.10 
As a feasibility trial, all quantitative endpoints were summarised 
descriptively, with no formal statistical comparisons between 
groups.
Qualitative data were audio recorded, transcribed verbatim 
and analysed following the framework method (see online 
supplementary document S1).
resulTs
recruitment and progress through trial
Each centre opened for 12 months; 409 patients were screened 
for eligibility and 64 randomised (16% of those screened; 
mean 5.3 per month) achieving the primary outcome of feasi-
bility (figure 1). Most participants had COPD (64%) or ILD 
(31%), and mMRC grade 4 (58%); 33% were taking opioids 
and HADS score was ≥15 in 24 (38%). Demographics and 
clinical characteristics were balanced between randomised 
groups (online supplementary tables S1, S2).
Main reasons for ineligibility were existing antidepressant 
use (38%), mMRC score <3 (27%). Eighty- three (20% of 409 
screened) patients declined participation. Reasons were mainly 
not liking the idea of a clinical (18%) or a blinded (7%) trial, 
not wanting to take additional medicine (18%), already having 
too much to think about (17%) and not liking the thought of 
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Table 1 Clinical activity outcomes and costs at day 28 of study by trial arm
Mirtazapine n=30 Placebo n=34
Clinical activity outcomes—mean (sd)
NRS worst (last 24 hours)* day 28
change from baseline to day 28 mean (95% CI)
6.3 (1.8)
–1.3 (–2.1 to −0.5)
7.1 (2.3)
–0.8 (–1.6 to 0.0)
NRS average (last 24 hours)* day 28
change from baseline to day 28 mean (95% CI)
4.7 (2.0)
–0.7 (–1.2 to −0.2)
4.9 (1.8)
0.0 (–0.7 to 0.7)
IPOS total* day 28 17.2 (8.0) 17.8 (7.6)
HADS anxiety* day 28 [HADS depression* day 28] 4.3 (2.8) [6.1 (3.3)] 5.3 (3.5) [6.5 (3.7)]
SPPB†‡ day 28 7.6 (2.1) 7.4 (2.9)
CRQ dyspnoea†§¶ day 28 [CRQ emotion†§ day 28] 3.1 (1.1) [5.0 (1.2)] 2.8 (1.0) [4.9 (1.3)]
CRQ fatigue†§ day 28 [CRQ mastery†§ day 28] 3.8 (1.3) [4.9 (1.2)] 4.0 (1.2) [4.9 (1.3)]
GSES total score† day 28 31.4 (5.1) 30.7 (4.8)
economic measures—mean (sd)
EQ- 5D† day 28
change from baseline to day 28 mean (95% CI)
0.61 (0.26)
0.07 (0.00 to 0.15)
0.63 (0.15)
0.03 (–0.04 to 0.09)
EQ- 5D VAS† day 28 63.4 (21.2) 60.8 (19.0)
Health and social care costs (£) in the previous 1 month* 522 (773) 412 (529)
*Scale interpretation: high score worse.
†Scale interpretation: high score better.
‡Missing data were higher for SPPB than other measures (see online supplementary table S3)
§CRQ subdomains averaged on the 1–7 scale to give comparability across subscales.
¶Not all patients completed all five activity subscales. However, scores were similar, the data for those completing all five activity subscales are provided here.
CRQ, Chronic Respiratory Disease Questionnaire; EQ- 5D, quality of life; GSES, General Self- Efficacy Scale; HADS, Hospital Anxiety and Depression Scale; HRQL, health- related quality of life; IPOS, 
Integrated Palliative care Outcome Scale; NRS, numerical rating scale/10; SPPB, Short Physical Performance Battery.
antidepressants (13%).
All randomised participants received at least one dose of 
mirtazapine or placebo, none were lost to follow- up (figure 1). 
Fifty- two participants (81%) remained on treatment all 28 days. 
Twenty- nine participants (45%) dose escalated at day 14; based 
on the same criteria at day 28, 21 participants (33%) would have 
been eligible for further dose escalation.
Twelve patients (six per arm) discontinued treatment prema-
turely. The Bang Blinding Index (BBI), which calculates differ-
ences between correct and incorrect guesses for unblinding (see 
online supplementary box S1), was 0.31 (95% CI 0.03 to 0.59) 
and 0.21 (95% CI −0.07 to 0.50) in the placebo and mirtazapine 
arms, respectively.
Toxicity and safety
There were few adverse events, with only one grade 3 reported 
(insomnia, day 28, placebo arm). There were 12 serious adverse 
events (SAEs) in nine participants (mean 1.3 per person, SD 
0.71; mirtazapine: four people (seven events), placebo: five 
people (five events)). Only one SAE (a fall, with grade 2 dizzi-
ness and confusion) was assessed as being related to trial medica-
tion (placebo arm). Two patients died during the study, after 27 
(mirtazapine) and 20 (placebo) days from baseline, both due to 
their underlying illness.
other outcome data
There were little missing data (online supplementary table S3). 
At baseline, mean scores for worst breathlessness NRS were 
similar across treatment arms, with SD of 1.52 informing the 
phase III sample size calculation. Worst breathlessness improved 
in both groups at day 7, staying similar subsequently (figure 2). 
Other outcomes also showed small changes over time (table 1, 
online supplementary figure S1).
Qualitative data
Interviews were conducted with 22 participants (11 COPD, 8 
ILD, 3 other) of whom two withdrew early because of adverse 
effects, see online supplementary box S2 for summary findings.
dIsCussIon
This feasibility trial successfully achieved its primary endpoint 
based on numbers recruited from three sites over 1 year, a 
pragmatic outcome based on completing a phase III study in a 
reasonable time. Uptake and data collection were high and attri-
tion low for a population with advanced disease.3 5 9 Qualitative 
data suggest this is partly due to having dedicated research staff. 
The tolerability and safety of mirtazapine were good with little 
apparent loss of participant blinding (BBI close to zero in both 
arms). Our data have been used to inform development of an 
international multicentre phase III trial; this has secured funding.
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